Avicenna journal of phytomedicine · 2026
Evaluation of nano-curcumin oral formulation efficacy in prevention of chemotherapy-induced adverse reactions in metastatic colorectal cancer patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jannati Yazdan Abad Mahdi, Allahyari Abolghasem, Kamandi Mostafa, Arasteh Omid, Varmaghani Mehdi, Karbasforooshan Hedyieh, Jaafari Mahmoud Reza, Kheradmand Hamidreza, Eftekhari Abolfazl, Elyasi Sepideh
Аннотация
OBJECTIVE: The aim of the present study is to evaluate the effectiveness of oral formulation of nano-curcumin in prevention of some chemotherapy-induced adverse reactions.
MATERIALS AND METHODS: In this study, 84 patients with metastatic colorectal cancer were randomly assigned into the nano-curcumin (40 mg capsule) or placebo groups, receiving treatments three times daily, beginning the first day to the end of the sixth cycle of chemotherapy. To investigate various adverse events, including hematologic adverse reactions, diarrhea, hand-foot syndrome (HFS) and neuropathy, the criteria of National Cancer Institute Common Terminology for Adverse Events (NCI-CTCAE) version 5 were implemented after the third and sixth course.
RESULTS: The CTCAE peripheral neuropathy score was significantly different between the two groups at the end of the 6th course (p=0.029) but not the third course (p=0.157). No significant response was observed for neutropenia, anemia, thrombocytopenia, HFS, or diarrhea at the end of both third (P=0.267, 0.258, 0.933, 0.377, and 0.811, respectively) and 6th courses (p=0.456, 0.645, 0.772, 0.34, and 0.114, respectively).
CONCLUSION: Nano-curcumin in dose of 40 mg thrice daily was not effective in prevention of neuropathy, HFS and hematologic adverse reactions induced by XELOX/FOLFOX-6 regimens. Further research with larger sample size on different nano-curcumin dosing schedules is suggested.
MATERIALS AND METHODS: In this study, 84 patients with metastatic colorectal cancer were randomly assigned into the nano-curcumin (40 mg capsule) or placebo groups, receiving treatments three times daily, beginning the first day to the end of the sixth cycle of chemotherapy. To investigate various adverse events, including hematologic adverse reactions, diarrhea, hand-foot syndrome (HFS) and neuropathy, the criteria of National Cancer Institute Common Terminology for Adverse Events (NCI-CTCAE) version 5 were implemented after the third and sixth course.
RESULTS: The CTCAE peripheral neuropathy score was significantly different between the two groups at the end of the 6th course (p=0.029) but not the third course (p=0.157). No significant response was observed for neutropenia, anemia, thrombocytopenia, HFS, or diarrhea at the end of both third (P=0.267, 0.258, 0.933, 0.377, and 0.811, respectively) and 6th courses (p=0.456, 0.645, 0.772, 0.34, and 0.114, respectively).
CONCLUSION: Nano-curcumin in dose of 40 mg thrice daily was not effective in prevention of neuropathy, HFS and hematologic adverse reactions induced by XELOX/FOLFOX-6 regimens. Further research with larger sample size on different nano-curcumin dosing schedules is suggested.